Research progress of DprE1 inhibitors as new anti-tuberculosis drugs

doi:10.3877/cma.j.issn.2095-655X.2022.03.012

Abstract

Abstract:

Tuberculosis continues to be one of the most serious infectious diseases threatening human health. At the moment, clinical use of anti-tuberculosis drugs has a poor therapeutic effect, has a high cost, has side effects, and has other flaws. As a result, there is an urgent need to develop new antitubercular drugs with new mechanism of action that are safer, more widely effective, and less toxic. Some progress has been made in the study of DprE1 inhibitors′ anti-tuberculosis effect in recent years. DprE1 inhibitors target the cell wall of mycobacterium tuberculosis and inhibit its growth by inhibiting the DprE1 enzyme that produces the mycobacterium tuberculosis cell wall.This paper reviewed DprE1 inhibitors interms of classification, mechanism of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, as well as drug safety, animal experiments, and clinical trials.

Key words: DprE1 inhibitors, Antitubercular agents, Pharmacological action

Lu Li, Shenjie Tang. Research progress of DprE1 inhibitors as new anti-tuberculosis drugs[J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(03): 207-210.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2022.03.012

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2022/V10/I03/207

References 26

[1]	World Health Organization.Global tuberculosis report 2021[R]．Geneva：World Health Organization，2021：17.
[2]	Zhang G, Howe M, Aldrich CC, et al. Spirocyclic and bicyclic 8-Nitrobenzothiazinones for tuberculosis with improved physicochemical and pharmacokinetic properties[J]．ACS Med Chem Lett，2019，10(3)：348-351.DOI：10.1021/acsmedchemlett.8b00634.
[3]	Kumar N，Srivastava R，Prakash A，et al.Virtual screening and free energy estimation for identifying mycobacterium tuberculosis flavoenzyme DprE1 inhibitors[J]．J Mol Graph Model，2021(102)：107770.DOI：10.1016/j.jmgm.2020.107770.
[4]	Kb S，Kumari A，Shetty D，et al.Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis[J]．J Mol Graph Model，2020(101)：107718.DOI：10.1016/j.jmgm.2020.107718.
[5]	Gao Y, Xie J, Tang R, et al. Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening[J]．Bioorg Chem，2019(85)：168-178.DOI：10.1016/j.bioorg.2018.12.018.
[6]	Whitehurst BC，Young RJ，Burley GA，et al.Identificationof 2-((2，3-dihydrobenzo[b][1，4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors[J]．Bioorg Med Chem Lett，2020，30(12)：127192.DOI：10.1016/j.bmcl.2020.127192.
[7]	Zhang G，Guo S，Cui H，et al.Virtual screening of small molecular inhibitors against DprE1[J]．Molecules，2018，23(3)：524.DOI：10.3390/molecules23030524.
[8]	Piton J，Vocat A，Lupien A，et al.Structure-Based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from mycobacterium tuberculosis[J]．Antimicrob Agents Chemother，2018，62(10)：e00681-18.DOI：10.1128/AAC.00681-18.
[9]	Balabon O，Pitta E，Rogacki MK，et al.Optimization of hydantoins as potent antimycobacterial decaprenylphosphoryl-β-d-ribose oxidase (DprE1) inhibitors[J]．J Med Chem，2020，63(10)：5367-5386.DOI：10.1021/acs.jmedchem.0c00107.
[10]	Liu L，Kong C，Fumagalli M，et al.Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents[J]．Eur J Med Chem，2020(208)：112773.DOI：10.1016/j.ejmech.2020.11277.
[11]	Liu R，Lyu X，Batt SM，et al.Determinants of the inhibition of DprE1 and CYP2C9 by antitubercular thiophenes[J]．Angew Chem Int Ed Engl，2017，56(42)：13011-13015.DOI：10.1002/anie.201707324.
[12]	Borthwick JA，Alemparte C，Wall I，et al.Mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose oxidase inhibitors: expeditious reconstruction of suboptimal hits into a series with potent in vivo activity[J]．J Med Chem，2020，63(5)：2557-2576.DOI：10.1021/acs.jmedchem.9b01561.
[13]	Imran M，A S A，Thabet HK, et al.Synthetic molecules as DprE1 inhibitors: a patent review[J]．Expert Opin Ther Pat，2021，31(8)：759-772.DOI：10.1080/13543776.2021.1902990.
[14]	Mariandyshev AO, Khokhlov AL, Smerdin SV, et al. The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone(PBTZ169)[J]．TeArkh，2020，92(3)：61-72.DOI：10.26442/00403660.2020.03.000621.
[15]	Dube PS，Legoabe LJ，Jordaan A，et al.Easily accessed nitroquinolones exhibiting potent and selective anti-tubercular activity[J]．Eur J Med Chem，2021(213)：113207.DOI：10.1016/j.ejmech.2021.113207.
[16]	Foo CS，Lechartier B，Kolly GS，et al.Characterization of DprE1-mediated benzothiazinone resistance in mycobacterium tuberculosis[J]．antimicrob agents chemother，2016，60(11)：6451-6459.DOI：10.1128/AAC.01523-16.
[17]	Guo S，Fu L，Wang B，et al.In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against mycobacterium tuberculosis[J]．Biomed Pharmacother，2020(131)：110777.DOI：10.1016/j.biopha.2020.110777.
[18]	Makarov V，Lechartier B，Zhang M，et al.Towards a new combination therapy for tuberculosis with next generation benzothiazinones[J]．EMBO Mol Med，2014，6(3)：372-383.DOI：10.1002/emmm.201303575.
[19]	Robertson GT，Ramey ME，Massoudi LM，et al.Comparative analysis of pharmacodynamics in the C3HeB/FeJ mouse tuberculosis model for DprE1 inhibitors TBA-7371, PBTZ169, and OPC-167832[J]．Antimicrob Agents Chemother，2021，65(11)：e0058321.DOI：10.1128/AAC.00583-21.
[20]	Lupien A，Vocat A，Foo CS，et al.Optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone macozinone (PBTZ169)[J]．Antimicrob Agents Chemother，2018，62(11)：e00840-18.DOI：10.1128/AAC.00840-18.
[21]	Spaggiari D, Desfontaine V, Cruchon S, et al.Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone(PBTZ169) and five active metabolites in human plasma[J]．PLoS One，2019，14(5)：e0217139.DOI：10.1371/journal.pone.0217139.
[22]	Zhang G，Sheng L，Hegde P，et al.8-cyanobenzothiazinone analogs with potent antitubercular activity[J]．Med Chem Res，2021，30(2)：449-458.DOI：10.1007/s00044-020-02676-4.
[23]	Li P，Wang B，Zhang X，et al.Identification of novel benzothiopyranone compounds against mycobacterium tuberculosis through scaffold morphing from benzothiazinones[J]．Eur J Med Chem，2018(160)：157-170.DOI：10.1016/j.ejmech.2018.09.042.
[24]	Grover S，Alderwick LJ，Mishra AK，et al.Benzothiazinones mediate killing of corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis[J]．J Biol Chem, 2014，289(9)：6177-6187.DOI：10.1074/jbc.M113.522623.
[25]	Hariguchi N, Chen X, Hayashi Y, et al. OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DprE1 inhibitor[J]．Antimicrob Agents Chemother，2020，64(6)：e02020-19.DOI：10.1128/AAC.02020-19.
[26]	Wang F，Sambandan D，Halder R，et al.Identification of a small molecule with activity against drug-resistant and persistent tuberculosis[J]．Proc Natl Acad Sci U S A，2013，110(27)：2510-2517.DOI：10.1073/pnas.1309171110.

Please choose a citation manager

Content to export